Nangibotide
Also known as: LR12, MOTREM
An investigational 12-amino-acid TREM-1 inhibitor peptide studied in septic shock and severe COVID-19. In clinical development; not approved.
Last updated
Mechanism of Action
Nangibotide is a synthetic 12-amino-acid peptide derived from TLT-1, a TREM-like protein. It acts as a decoy that binds the ligand of TREM-1, a receptor on neutrophils and monocytes that amplifies inflammatory signaling during infection. By blocking TREM-1 activation it aims to dampen the excessive inflammation and vascular dysfunction of septic shock without fully suppressing immunity. Trials enrich for patients with high soluble TREM-1 levels, the group thought most likely to benefit.
- Half-life
- Not well established
- Administration Routes
- Intravenous
- Research Status
- Clinical
Reported Benefits
- Phase 2a and 2b trials in septic shock (ASTONISH)
- Phase 2 trial in critically ill COVID-19 patients (ESSENTIAL)
- Biomarker-guided (sTREM-1) patient selection approach
Potential Side Effects
- Generally similar to placebo in Phase 2 trials
- Long-term and rare adverse effects not established
Common Dosing
No approved dose. Trial regimens have used continuous IV infusion for up to about 5 days in intensive care, with doses set by body weight. Use outside a clinical trial is not appropriate.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Investigational: not established
No documented stacking partners for Nangibotide yet.
- View
Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial
2020
- View
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial
2023